Dendreon Pharmaceuticals LLC
Records under this name other than the patents Dendreon Pharmaceuticals LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Back to Dendreon Pharmaceuticals LLC
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,572,444 | Binding Proteins Specific for Human Matriptase Term ended Term ended Dec 16, 2025 · High confidence | Term ended | Term ended Dec 16, 2025 | High confidence |
| US RE43,298 | Peptides as NS3-SERINE Protease Inhibitors of Hepatitis C Virus Formerly held Term ended Term ended Dec 22, 2024 · Low confidence | Term ended | Term ended Dec 22, 2024 | Low confidence |
| US 7,132,398 | Method of Treatment of Hemorrhagic Disease Using a Factor Viia/Tissue Factor Inhibitor Term ended Term ended Jan 29, 2024 · High confidence | Term ended | Term ended Jan 29, 2024 | High confidence |
| US 7,413,869 | Method for Determining Potency of Antigenic Presenting Cell Based Vaccines Term ended Term ended Nov 12, 2022 · High confidence | Term ended | Term ended Nov 12, 2022 | High confidence |
| US 6,962,795 | Neutrophil inhibitors Term ended Term ended Nov 8, 2022 · From the USPTO record | Term ended | Term ended Nov 8, 2022 | From the USPTO record |
| US 7,169,760 | Novel Peptides as NS3-SERINE Protease Inhibitors of Hepatitis C Virus Formerly held Term ended Term ended Nov 6, 2022 · High confidence | Term ended | Term ended Nov 6, 2022 | High confidence |
| US 7,772,266 | Small-Molecule Modulators of TRP-P8 Activity Lapsed on the fee record Ended Aug 10, 2022 · High confidence | Lapsed on the fee record | Ended Aug 10, 2022 | High confidence |
| US 7,244,721 | Novel Peptides as NS3-SERINE Protease Inhibitors of Hepatitis C Virus Term ended Ended no later than Apr 15, 2022 · Medium confidence | Term ended | Ended no later than Apr 15, 2022 | Medium confidence |
| US 8,658,177 | Promiscuous HER-2/Neu CD4 T cell epitopes Lapsed on the fee record Ended Feb 25, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 25, 2022 | From the USPTO record |
| US 7,659,117 | Compositions and methods for dendritic cell-based immunotherapy Lapsed on the fee record Ended Feb 9, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 9, 2022 | From the USPTO record |